Streetwise Reports' Article Archives — March 2017 back to current month (6)

3D Signatures' TeloView Can Diagnose Alzheimer's with Cheek Swab (03/30/2017)

With a swab taken from the inside of a patient's cheek, 3D Signatures' TeloView platform has demonstrated its ability to diagnose Alzheimer's disease, and also to assess whether the disease is manifesting in a mild, moderate or severe form.


Therapix IPO on NASDAQ Could Catapult It into the Big Leagues (03/21/2017)

Therapix Biosciences launches its IPO on NASDAQ on Wednesday, March 22, under the trading symbol TRPX. The Tel Aviv-based company specializing in the development and commercialization of cannabinoid-based treatments has a drug for Tourette Syndrome in Phase 2a trials and is additionally developing a drug for mild cognitive impairment. The IPO helps put it on a path to join much larger companies developing cannabinoid-based drugs.


RepliCel's Phase 1 Trial for Hair Loss Completed Successfully (03/16/2017)

RepliCel's successful conclusion of its Phase 1 trial for hair loss sets it up for the next steps in the drug's development.


3D Signatures' Disruptive Technology Moving Ahead for Prostate Cancer and Hodgkin's Lymphoma (03/08/2017)

3D Signatures continues to advance its cutting-edge technology for prostate cancer liquid biopsies and Hodgkin's lymphoma tests.


Stellar Biotechnologies (SBOT:NASDAQ) Inks Multiyear KLH Supply Agreement with Amaran Biotechnology; Stellar Up 13% on News (03/02/2017)

Stellar Biotechnologies and Amaran Biotechnology have entered into an exclusive agreement where Stellar will supply KLH to the biopharmaceuticals manufacturer.


Stellar Biotechnologies (SBOT:NASDAQ) Could Rise with KLH Vaccine Trial Success (03/01/2017)

Several KLH-based vaccines are in trials for indications as varied as breast cancer and lupus, and clinical success could propel Stellar Biotechnologies, which is the only provider of KLH that has its own aquaculture facilities, says Jason McCarthy, an equity research analyst with Maxim Securities. Maxim currently has a price target of $4 on Stellar and the stock currently trades at around $1.65.


More Archives

2023Aug Jul Jun May Apr Mar Feb Jan

2022Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2021Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2020Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2019Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2018Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Notable Quotes